智翔金泰：GR1803注射液被纳入优先审评品种名单

Core Viewpoint - The company Zhixiang Jintai announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration, targeting adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of treatment [1] Group 1 - GR1803 injection is a bispecific antibody drug developed independently by the company, classified as a Class 1 therapeutic biological product [1] - The new drug application still needs to go through multiple stages, and there is uncertainty regarding the product's successful market launch and the timeline for its availability [1]